FRENCH BIOTECH AND PHARMA COMPANIES · french biotech and pharma companies bio europe 2o13 4-6...
34
FRENCH BIOTECH AND PHARMA COMPANIES BIO EUROPE 2O13 4-6 NOVEMBER - VIENNA
Transcript of FRENCH BIOTECH AND PHARMA COMPANIES · french biotech and pharma companies bio europe 2o13 4-6...
FRENCH BIOTECHAND PHARMA COMPANIES
BIO EUROPE 2O13 4-6 NOVEMBER - VIENNA
2
INSTITUTIONAL PARTNERS (cLUSTERS, RESEARch INSTITUTES)ATLANPOLE BIOTHERAPIES ..............................................................................................................................................................................6
MEDICEN PARIS REGION .......................................................................................................................................................................................6
GENOPOLE .................................................................................................................................................................................................................................7
SATT IDfINNOv ....................................................................................................................................................................................................................7
cOMPANIESAffILOGIC ...............................................................................................................................................................................................................................10
ALIZE PHARMA .................................................................................................................................................................................................................10
ALSACE INTERNATIONAL ..................................................................................................................................................................................11
AMYLGEN ..................................................................................................................................................................................................................................11
ARIANA PHARMACEuTICALS .......................................................................................................................................................................12
ATLANTIC BONE SCREEN .................................................................................................................................................................................12
BIOALTERNATIvES .......................................................................................................................................................................................................13
BIOMEDICAL TISSuES ............................................................................................................................................................................................13
BIOPHYTIS ...............................................................................................................................................................................................................................14
BIO-XTAL ...................................................................................................................................................................................................................................14
CARLINA TECHNOLOGIES .................................................................................................................................................................................15
CELLvAX .....................................................................................................................................................................................................................................15
CILOA ..............................................................................................................................................................................................................................................16
CITOXLAB .................................................................................................................................................................................................................................16
CYTuNE PHARMA .........................................................................................................................................................................................................17
DOMAIN THERAPEuTICS....................................................................................................................................................................................17
DRuGABILIS .........................................................................................................................................................................................................................18
EuKARYS ...................................................................................................................................................................................................................................18
GENBIOTECH .....................................................................................................................................................................................................................19
2
CONTENTS
3
CONTENTS
GLOBAL CARE ....................................................................................................................................................................................................................20
ICTA ...................................................................................................................................................................................................................................................22
IN-CELL-ART ......................................................................................................................................................................................................................22
IRIS PHARMA ......................................................................................................................................................................................................................23
KEOSYS ........................................................................................................................................................................................................................................23
L2D SERvICES ...................................................................................................................................................................................................................24
LPS-BIOSCIENCES ......................................................................................................................................................................................................24
MEDINCELL ..........................................................................................................................................................................................................................25
METABOLYS ...........................................................................................................................................................................................................................25
METABRAIN RESEARCH ......................................................................................................................................................................................26
MYELOMAX .............................................................................................................................................................................................................................26
OTR3 ................................................................................................................................................................................................................................................27
OXELTIS .......................................................................................................................................................................................................................................27
PELvIPHARM .......................................................................................................................................................................................................................28
PORSOLT ...................................................................................................................................................................................................................................28
POXEL ............................................................................................................................................................................................................................................29
PRESTwICK CHEMICAL .......................................................................................................................................................................................29
PuP PHARMA .....................................................................................................................................................................................................................30
PX’THERAPEuTICS .....................................................................................................................................................................................................30
QuINTEN ...................................................................................................................................................................................................................................31
SKuLDTECH..........................................................................................................................................................................................................................31
SYNCROSOME ....................................................................................................................................................................................................................32
TEXCELL ....................................................................................................................................................................................................................................32
TROPHOS ..................................................................................................................................................................................................................................33
vfP THERAPIES ..............................................................................................................................................................................................................33
5
INSTITuTIONAL PARTNERS (CLuSTERS, RESEARCH INSTITuTES)
5
6
Date of creation: 2005
Date of creation: 2005
MEDIcEN PARIS REGION, excellence at the heart of Europe MEDIcEN PARIS REGION is your best gateway to access European biotechnologies and markets. Our mission is to maintain and reinforce the Paris Region as Europe’s leading industrial center for diagnostic innovation and health technologies.3 R&D themes: 1) Translational medicine; 2) Biological tools for industrial use, biotherapeutic products; 3) Digital biology.3 consolidated disease areas and 2 arising areas: 1) Cancer 2) Neurology 3) Infectiology 4) Cardiometabolism 5) Rare diseases.
cONTAcT: Francois chEVILLARD [email protected]
3-5, impasse Reille 75014 PARIS Tel: +33 (0)1 79 68 10 86 www.medicen.org
MEDICEN PARIS REGION
ATLANPOLE BIOThERAPIES gives you access to extended skills, from biodiagnostics to biomedicine in 3 major areas: immunobiotherapies, radiopharmaceuticals and regenerative medicine. For pharmaceutical companies looking for high level partners devoted to healthcare and biotech, ATLANPOLE BIOThERAPIES is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France.
cONTAcT: Gregory [email protected]
95, route de Gachet Château de la Chantrerie44307 NANTES Cedex 3 Tel: +33 (0)2 40 25 27 20 www.atlanpolebiotherapies.fr
ATLANPOLE BIOTHERAPIES
SECTOR: Competitivness cluster
SECTOR: Competitivness cluster
7
Date of creation: 1998
GENOPOLE® is the leading French Science Park dedicated to life sciences.
Located in the Paris Region Biocluster, 30 km south of the city, we offer business support and incubation to biotech companies in biopharmaceuticals, diagnostics, medical devices, scientifi c instrumentation, agrifood, environment and chemistry. We also assist French and foreign companies in establishing their R&D, commercial or industrial operations in the southern Paris Biocluster to benefi t from world-class hospitals, higher University education, biotech and pharma companies.• 71 companies• 21 academic research labs• 2 148 staff
cONTAcTS: Patricia [email protected]
Frédéric [email protected]
5, rue Henri Desbruères Genopole Campus 1 91030 Evry CedexTel: +33 (0)1 60 87 83 00 genopole.fr
SECTOR: • Other: (developpement agency, association, institution, cluster)THERAPEuTIC AREA: • Cardiovascular • Diseases of the blood, immune disorders • Disease of ear or eyeMEMBER Of COMPETITIvE CLuSTER: Medicen
GENOPOLE
SATT IDfINNOv
5, avenue d’Italie75013 PARIS Tel: +33 (0)1 44 23 21 50 www.idfi nnov.com
cONTAcT: William VIcKERYDirecteur de la Business Unit Santé william.vickery@idfi nnov.com
SECTOR: Other: (developpement agency, association, institution, cluster)Technology Transfer Offi ce.THERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
IDFINNOV is a French TTO holding exclusive rights to detect, seed-fund and commercialize technology stemming from a vast academic territory (340 research labs, 17 000 researchers and clinicians) in and around Paris. Idfi nnov operates as a seed-fund and will invest over €6m/year to fi nance proof-of-concepts studies and prototyping projects on carefully selected innovations. IDFINNOV is committed to facilitating due diligences for IP-related alliances and start-up creations.
Date of creation: 2012Nombre d’employés: 22
9
Date of creation: 1996 Nombre d’employés: 43
Date of creation: 1996 Nombre d’employés: 43
BIOTECHS COMPANIES
9
10
Date of creation: 2010
ALIZÉ PhARMA is a group of companies specialized in the development of innovative biopharmaceutical drugs for the treatment of metabolic diseases and rare diseases. ALIZÉ PhARMA SAS is dedicated to AZP-531, a peptide derived from unacylated ghrelin, currently in Phase I, to be developed in type 2 diabetes, the Prader Willi syndrome and some ischemia-related cardiovascular conditions. ALIZÉ PhARMA II SAS, is focused on ASPAREC®, a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, currently undergoing Phase I clinical development.
cONTAcT: Valérie WESLEY [email protected]
15, chemin du Saquin Espace europeen - BAT G 69130 ECULLY Tel: +33 (0)4 72 18 94 28www.alz-pharma.com
SECTOR: Therapeutics THERAPEuTIC AREA: • Endocrine&metabolic diseases • Cancer, Oncology
ALIZE PHARMA
AFFILOGIc is a biotech company developing a new class of affi nity ligands, Nanofi tins®, which are able to selectively bind many targets and have proven excellent tools for:• Targeting (immunolocalization, in vivo neutralization): Therapeutic applications• Capture (affi nity chromatography, protein removal): Bioprocessing applications• Detection (immunoassays, Western Blot): Diagnostic applications.
cONTAcT: Nadège PRELBusiness Development Manager nadege@affi logic.com
2, rue de la Houssinière 44000 NANTES Tel: +33 (0)2 51 12 56 95 www.affi logic.com
SECTOR: • Therapeutics • DiagnosticTHERAPEuTIC AREA: • Digestive system • Disease of ear or eye • Disease of nervous system
AffILOGIC
11
AMYLGEN has developed a unique and proprietary know-how on Alzheimer’s disease rodent models based on central injection of amyloid peptide fragments with validated predictive value. Other models for schizophrenia, dépression, stroke are also available. AMYLGEN’s models and techniques allow fast-scale screening and pre-clinical validation for the pharmaceutical development of new drug candidates at a very early stage of development.
ALSAcE INTERNATIONAL is the economic development agency of the Alsace region and an active member of the Alsace BioValley Cluster, a unique environment, rich in business and research opportunities. Alsace International provides free and confi dential customized services to companies interested in exploring Alsace as a possible location in Europe to carry out activities including R&D, Service providing, Sales and Marketing, Manufacturing, Regional Headquarters, Clinical trials, collaborative research (public or private collaborations)…
cONTAcT: Vanessa VILLARD [email protected]
cONTAcTS: Patricia hATESUERBusiness Development Manager [email protected]
Andrew cLUTZDirector, Business Development
Place Eugene Bataillon CC105 34095 MONTPELLIER Tel: +33 (0)4 67 14 36 86 www.amylgen.com
Le Sebastopol3, Quai Kléber 67000 STRASBOURG Tel: +33 (0)3 88 24 77 68 www.alsace.com
SECTOR: Developpemnt agency
SECTOR: R&D services/biotechnologiesTHERAPEuTIC AREA: • Disease of nervous system
AMYLGEN
ALSACE INTERNATIONAL
Date of creation: 1/10/2009Number of employees: 6
Number of employees: 25
International Offi ceALSACE INTERNATIONAL 40 Wellesley StreetWeston, MA 02493 USATel: +1 (781) 894 7486Mob. +1 (617) 306 1541
12
Date of creation: october 2005Number of employees: 10
ATLANTIc BONE ScREEN is a French Preclinical CRO providing biological evaluation services in the fi eld of bone and joint diseases and in the fi eld of bone tumors. We provide In vitro assays( bone and joint cells, tumor cells), In vivo assays (Experimental models in mice and rats: osteoporosis, osteoarthritis, rheumatoid arthritis, osteosarcoma, bone metastases from breast and prostate cancer), ex vivo analyses (histology, immunohistochemisty, imagery, ELISA assays).ATLANTIc BONE ScREEN has an affi liated company, ATLANCHIMPHARMA provides custom-made chemical synthesis services
cONTAcT: Elisabeth PORchER [email protected]
3, rue Aronnax 44821 SAINT HERBLAIN Cedex Tel: +33 (0)2 40 41 11 25 www.atlantic-bone-screen.com
SECTOR: R&D services/biotechnologiesTHERAPEuTIC AREA: • Cancer, oncology
ATLANTIC BONE SCREEN
BIOALTERNATIvES
ARIANA® accurately identifi es the best patient responder sub-groups in clinical trials, and optimizes biomarker/diagnostic signatures using its unique technology. ARIANA applies its proprietary “rules-based” data analytical approach – KEM® - to clinical datasets to identify complex relations that all other approaches miss, thus enabling decision-makers to optimize all possible endpoints simultaneously. ARIANA’s world-class team of experienced, inter-disciplinary scientists includes PhD biologists, computer scientists, biostatisticians, bio-informatics specialists, chemists and clinical experts. ARIANA was founded in 2003 as a spin-off from the Institut Pasteur, and has offi ces in Paris, France and Cambridge, Mass, USA.
cONTAcT: Mohammad AFShARChairman & CEO [email protected]
28, rue du Docteur Finlay 75015 PARIS Tel: +33 (0)1 44 37 17 00 www.arianapharma.com
SECTOR: • Therapeutics • DiagnosticTHERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
ARIANA PHARMACEuTICALS
International Offi ceAriana Data IntelligenceInc. One Broadway - 14th Floor Cambridge, MA 02142 - USA
Date of creation: 2003
13
BIO ALTERNATIvES
BIOALTERNATIVES is a private company (Contract Research Organization) specialized in Cellular and Molecular Pharmacology. BIOALTERNATIVES provides services to support the early stages of drug discovery and the claim substantiation of healthcare compounds using up-to-date in vitro solutions.
cONTAcT: Maxance [email protected]
1bis, rue des Plantes86160 GENÇAYTel: +33 (0)5 49 36 11 37 www.bioalternatives.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Diseases of the blood, immune disorders • Disease of nervous system • Endocrine&metabolic diseases
Date of creation: 1996Number of employees: 43
Date of creation: 01/10/2010Number of employees: 4
BIOMEDIcAL TISSUES is a Medtech company dedicated to the development of implantable medical devices for regenerative medicine.The company provides his customers with services in the fi eld of implants surface treatment (ISO13485 certifi ed). Besides, Biomedical Tissues develops medical devices, based on a unique technology of synthetic polymer microfi bers synthesis, for soft tissues regeneration.
cONTAcT: Valérie [email protected]
IRT UN8, quai Moncousu44000 NANTESTel: +33 (0)2 28 08 00 37www.biometiss.com
SECTOR: • Therapeutics • R&D services/biotechnologiesTHERAPEuTIC AREA: • Cardiovascular • Skin&subcutaneous tissue
BIOMEDICAL TISSuES
14
Date of creation: 2006Number of employees: 10
BIOPHYTIS
BIOPhYTIS, a research company in health and nutrition focusing on metabolic disorders and age-related diseases. It is developing a portfolio of nutraceuticals and drug candidates derived from active natural substances targeted at metabolic disorders and age-related diseases. Its portfolio includes two proprietary nutraceuticals clinically tested for obesity treatment and for skin photoprotection. It also includes two drug candidates at pre-clinical stages for the treatment of sarcopenic obesity and age-related macular degeneration.
SECTOR: • TherapeuticsTHERAPEuTIC AREA: • Disease of ear or eye• Endocrine&metabolic diseases
cONTAcT: Stanislas VEILLET [email protected]
102, avenue Gaston Roussel 93230 ROMAINVILLE Tel: +33 (0)1 41 83 66 00 www.biophytis.com
International Offi ceSAO PAULO, BRÉSIL
Date of creation: 1998Number of employees: 15
BIO-XTAL is a pioneer service provider for X-Ray & NMR structure resolution services with particular strong expertise in insect and mammalian cells based expression systems. Recently, our company has started an intensive program on purifi cation of membrane proteins proposing the fi rst ready to use purifi ed receptor catalogue offer on GPCRs and Ion Channels
International Offi ceGrand Rue 561095 LUTRY SWITZERLAND
cONTAcT: Etienne L’hERMITE [email protected]
227, route de la Chapelle 74540 ST FELIX www.bioxtal.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Cancer, oncology
BIO-XTAL BIO TAL
15
Date of creation: 2001
cELLVAX is a French SME which provides complete preclinical innovating drug validation studies both in vitro and in vivo (rodents and non-rodents) allowing to accelerate the drug development process for unmet needs related with severe human diseases, mainly in cancer fi eld.
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Diseases of the blood, Immune disorders • Cancer, Oncology
cONTAcT: Ming WEI [email protected]
4, rue Pierre Fontaine 91058 EVRY Tel: +33 (0)1 43 76 32 65 www.cellvax-pharma.com
CELLvAX
cONTAcT: Olivier MEYER [email protected]
cARLINA TEchNOLOGIES is a biopharmaceutical company specialized in the development of micro- and nano-medicines. The company provides R&D formulation development services to the pharmaceutical, veterinary and biotechnology industries as well as it develops improved versions of fi rst generation drugs for the treatment of cancer and diabetes using innovative encapsulation platforms.
22, rue Roger Amsler49100 ANGERS Tel: +33 (0)2 41 24 92 82 www.carlinatech.com
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Endocrine&metabolic diseases • Cancer, Oncology
CARLINA TECHNOLOGIES
Date of creation: 23 juillet 2010
16
Date of creation: 1969Number of employees: 850
cITOXLAB, a leading non-clinical CRO (France, Canada, Denmark and Hungary) offers in vitro and in vivo safety studies. With more than 40 years of experience in safety and general pharmacology, genotoxicology, genomics, DART, immunotoxicology, pathology, dermal, ocular, inhalation, infusion, and carcinogenicity testing, along with ADME and bioanalysis. Our facilities are GLP and AAALAC certifi ed.
ciToxLAB North America445, Armand-Frappier BlvdLaval, Quebec H7V 4B3 - CANADA
ciToxLAB hungaryVeszprém, Szabadságpuszta8200, HUNGARY
ciToxLAB ScantoxHestehavevej 36A, EjbyDK-4623 Lille SkensvedDENMARK
B.P. 563 - 27005 EVREUX CedexTel: +33 (0)2 32 29 26 26 www.citoxlab.comcONTAcT: Stéphane DE [email protected]
SECTOR: Other: (developpement agency, association, institution, cluster)CRO - Preclinical services
CITOXLAB
Date of creation: 2011Number of employees: 8
CILOA
cILOA offers custom production of fully native membrane proteins on exosomes, therapeutic mAbs against membrane proteins and collaboration for vaccine development. Ciloa has a full pipeline for mAb development with: 1. fully native membrane antigens (GPCRs, Kinase receptors, Ion channels, Viral Envelope proteins, etc.). 2. Hybridoma dev. with proprietary powerful immunization protocol. 3. Proprietary Human scFv Phage library focused on membrane Antigens. 4. ELISA screening & SPR characterization.
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
cONTAcT: Robert [email protected]
Bat. 24, cc107 Universite Montpellier 2Place E. Bataillon 34095 MONTPELLIER Cedex 5Tel: +33 (0)4 67 14 39 97www.ciloa.fr
17
Date of creation: 2007
Date of creation: 2008Number of employees: 30
cYTUNE develops CYP0150 that uniquely mimics the major MoA of IL-15 even in pathologic conditions. CYP0150 restores a potent but balanced immune response and is a unique opportunity within the successful family of anti-immunosuppressive agents such anti-CTLA4 and anti-PD1. CPY0150 alone and in combination was shown to have promizing effi cacy in different animal tumor models and to be superior to IL-2. Moreover, cYTUNE develops a broad portfolio of potent immunocytokines, i.e. monoclonal antibody fused to CYP0150. These ICKs enable to manage the product Life Cycle Management for existing blockbusters and to increase the effi cacy of existing or future antibodies.
DOMAIN ThERAPEUTIcS is a French biopharmaceutical company dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs). DOMAIN uses its innovative and proprietary technology platforms DTect-AllTM and Biosensors to both identify orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) and to determine the intracellular pathways underlying the physiological effect. The company’s pipeline is composed of new chemical entities ranging from hits to optimized leads targeting hot GPCRs for leading indications (CNS and metabolic diseases).
cONTAcTS: Didier cOQUOZPharmD, PhD, CDO/C BD&[email protected]
David Bechard, PhD, MBA, President, [email protected]
cONTAcT: Marjorie SIDhOUMBusiness Development Manager
7, avenue Amédée Ménard 44300 NANTES Mob.: +33 (0)6 66 49 55 94 www.cytunepharma.com
BIOPARC850, boulevard Sebastien Brant 67400 STRASBOURG Tel: +33 (0)3 90 40 61 50 www.domaintherapeutics.com
SECTOR: Therapeutics THERAPEuTIC AREA: • Cancer, Oncology
SECTOR: • Therapeutics • R&D services/biotechnologiesTHERAPEuTIC AREA: • Disease of nervous system • Endocrine&metabolic diseases • Cancer, oncology
CYTuNE PHARMA
DOMAIN THERAPEuTICS
18
High performance high yield cell-free messenger RNA production systems for research, cell therapies, human vaccines, cell reprogramming. The C3P3® mRNA Production System has three decisive competitive advantages: 1) increased mRNA yields; 2) fully mature mRNA with very high rate of native capping, and poly(A)tail, enhancing protein expression; 3) Easy-to-Use and Quick: One-step process instead of 3 or 4 to a produce completely capped, poly(A)-tailed mRNA. Other advantages: stability, immunogenicity, poly(A)-tails of equal or customized length, non-viral.
cONTAcT: Benjamin [email protected]
Pépinière « Genopole Entreprises » -CAMPUS 3 - 4, rue Pierre Fontaine91058 EVRY CedexMob.: +33 (0)6 24 00 17 53 www.eukarys.com
SECTOR: • Therapeutics • R&D services/biotechnologies
EuKARYS
Date of creation: 210Number of employees: 3
Date of creation: 2004
DRUGABILIS is a CRO specialized in pharmaceutical physicochemical characterization and formulation as applied to the early selection of new drug candidates and their formulations. DRUGABILIS management and scientists have an extensive experience of industrial pharmaceutical research support. The company offer includes solubility and stability screenings, salt and polymorphism screenings, formulation design for animal dosing (any route of administration/any animal model/low-soluble compounds...), preformulation studies, phase I formulation strategy set-up.
cONTAcT: Joel VAcUS [email protected]
5, rue Jean Baptiste Clément 92290 CHATENAY MALABRY Tel: +33 (0)1 46 61 28 50 www.drugabilis.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system • Diseases of the blood, immune disorders
DRuGABILIS
19
Date of creation: 24/10/2012
The creation of GENBIOTEch, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the fi eld of rheumatology, dermatology and gynecology worldwide.GENBIOTEch aims to bring together people and resources required for Research and Development and Marketing innovative biotechnological therapies adapted to patients’ needs.
cONTAcT: [email protected]
Z.I. les 3 Moulins280, rue de Goa - B.P. 60053 06901 SOPHIA-ANTIPOLIS Tel: +33 (0)4 92 91 32 23 www.genbiotech.com
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Diseases of the blood, immune disorders • Skin&subcutaneous tissue
GENBIOTECH
20
GLOBAL cARE is an outstanding consortium of 5 French expertise centers (honored by the Carnot institute label) research that covers 4 therapeutic fi elds of major interest in human health: oncology, ophthalmology, infectious diseases and neurology.Supported by our past experience in partnership research and in property management and by the fame of its members, GLOBAL cARE targets the international health market on emerging imaging technologies, innovative diagnostic tools and therapeutic advances.
GLOBAL cARE offers behind a joint counter enlarged opportunities to our industrial and research partners worldwide. Bringing greater visibility to our R&D offers, GLOBAL cARE aims at mobilizing multi-disciplinary expertises in response to enterprise needs.More detailed informations on the GLOBAL cARE consortium members below:Pasteur MI (Maladies Infectieuses)The “Pasteur Maladies Infectieuses” (“Pasteur Infectious Diseases”) Carnot institute includes fi ve specialized departments of the “Institut Pasteur” (Virology, Microbiology, Parasitology & Mycology, Infection & Epidemiology, Cell Biology & Infection) that, together with four technological platforms, are dedicated to research on infectious diseases. It brings together basic and applied research activities involving numerous research partnerships with SMEs and large pharmaceutical and diagnostic companies.The goal of research performed at the “Pasteur MI” Carnot institute is to understand basic mechanisms of host cells / pathogen interaction, to develop tools to diagnose known or emerging pathologies, and to perform the clinical validation of vaccines and therapeutic treatments. These works aim at providing an answer to today’s society expectations in public health problems, whether in developed countries (in particular AIDS, antibiotic resistance) or in developing countries (diseases of parasitic origin).
« Seeing & hearing Institute »Built in the heart of Paris, the «Seeing and Hearing» Carnot Institute is one of the most important research center in Europe on eye and audition diseases.Conceived as a place of gathering and exchanges, it brings together the three major actors of the fi ght against visual and auditive impairments: researchers, clinicians and industrial partners. This proximity enables the sharing of ideas, skills and platforms, the emergence of new questions and facilitates the delicate process of translating fundamental discoveries into new treatments.Our research and development activities are focused onto retinal neuroprotection, sensory readaptation, innovation in clinical investigation (imaging, diagnosis, surgery) and new solutions for the visually impaired people (smart-home, smart-city, accessible services).The Institute’s goal is to discover, test and develop treatments and technological innovations of tomorrow in order to prevent or limit visual and auditive impairment and to improve the autonomy and the quality of life of patients.
cONTAcT: Jean-Philippe ARIÉ [email protected]
INSTITUT PASTEUR BÂTIMENT LWOFF28, rue du Docteur Roux75724 PARIS Cedex 15Tel: +33 (0)1 45 68 89 18 - Fax: +33 (0)1 45 68 86 57Mob.: +33 (0)6 85 67 71 25
GLOBAL CARE
THERAPEuTIC: Oncology...
21
IcM is a private, not-for-profi t, Translational Neuroscience Institute based in Paris, France an rooted in Pitie-Salpetriere, the largest French Neurology Hospital. IcM aggregates more than 500 researchers, a clinical research facility, numerous technological platforms and a start-up incubator within the same building. Main research fi elds include Parkinson’s disease, Alzheimer, Huntington, ALS, epilepsy, Multiple Sclerosis and Neurooncology, with a total of +50 clinical trials ongoing. It is also the national reference center for 13 rare neurological diseases.
ThE cURIE INSTITUTE is a leading comprehensive Cancer Center in Paris, France, founded by Marie Curie in 1909. Our Technology Transfer&Licensing Department” is looking for industrial partners to develop patended innovation (120 families), to enter into preclinical R&D collaboration (drug discovery…) as well as into early-stage clinical collaborations.
cONTAcT: Alexis GENINDirecteur des Applications de la Recherche [email protected]
BRAIN & SPINE INSTITUTE (ICM)Hôpital Pitié Salpêtrière47, boulevard de l’Hôpital 75013 PARIS Tel: +33 (0)1 57 27 40 00 http://research.icm-institute.org/
GLOBAL CARE
24, rue Salomon de Rothschild - 92288 Suresnes - FRANCETél. : +33 (0)1 57 32 87 00 / Fax : +33 (0)1 57 32 87 87Web : www.carrenoir.com
INSTITUTION DU CERVEAU ET DE LA MOELLE EPINIEREICM_09_2742_LogoAn_Quad26/08/2009
ÉQUIVALENCES QUADRI
MAGENTA 70% JAUNE 100%
CYAN 100% MAGENTA 70% NOIR 60%Ce fichie r est un documen t d’exécutio n créé sur
Illustrator version 10.
22
IcA was founded in 2005 by a research team including a Nobel Prize laureate. IcA is specialized in nanocarriers for macromolecule delivery and it has collaborations with DARPA (US Ministry of Defense), Sanofi Pastuer, Merial and more. In 2012, Deloitte awarded ICA as one of the fastest growing biopharmaceutical fi rms between 07 and 11 in France. Currently, IcA has 4 core activities based on the delivery system: Vaccine, Gene Therapy , Antibody Discovery and iPSc,
cONTAcT: Sohei FUKUYAMAMBA Business Development & Alliance [email protected]
21, rue de la Noue Bras de Fer44200 NANTESTel: +33 (0)2 40 71 67 17 www.incellart.com
SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologies THERAPEuTIC AREA: • Infectious and parasistic diseases • Cancer, oncology
IN-CELL-ART
Date of creation: 2005
Date of creation: 01/05/1984Number of employees: 350
IcTA (INTERNATIONAL cLINIcAL TRIALS ASSOcIATION) is an international privately-owned CRO with 30 years of experience in clinical R&D, pharmaco-epidemiology and expanded access programs for APIs, cell therapies, diagnostics and medical devices. IcTA’s international operations in Europe and the USA provide full clinical research or “a la carte” services in traditional and adaptive clinical trials from Early Phase to Late Phase across a broad range of therapeutic areas...
cONTAcT: Olivier hUMBEY [email protected]
International Offi ceICTA GmbH - Lebacher Strasse 4 - D-66113Saarbrücken
ICTA – INTERNATIONAL CLINICAL TRIALS ASSOCIATION11, rue du Bocage21121 FONTAINE LES DIJON Tel: +33 (0)3 80 53 40 00 www.icta.fr
SECTOR: • Therapeutics • R&D services/biotechnologies • DiagnosticTHERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
ICTA
23
Date of creation: 1989Number of employees: 60
A leading contract research organization (CRO) dedicated to ophthalmology, IRIS PhARMA helps clients around the world navigate every stage of the drug and device development process – including in vivo screening, proof of concept, ocular effi cacy, GLP preclinical studies, bioanalysis, clinical trials, and marketing surveys. IRIS PhARMA has partnered with clients to bring more than 40 ocular drugs and medical devices to market in the past 24 years, in addition to offering consulting services to help clients determine the best indication for molecules and products in development. This CRO has expertise in all ophthalmic indications, and supports clients ranging from small start-ups to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.
cONTAcT: Pierre-Paul [email protected]
Allée Hector Pintus06610 LA GAUDETel: +33 (0)4 93 59 49 59www.iris-pharma.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Disease of ear or eye
IRIS PHARMA
Date of creation: 2001
KEOSYS Medical Imaging is a global company specialized in IT applied to Medical Imaging within clinical research and medical diagnosis. KEOSYS offers full medical imaging services for phase II-III-IV drug and device medical imaging clinical trials whatever the imaging modalities and the therapeutic areas. KEOSYS’ expertise relies on its deep knowledge of the medical imaging requirements in clinical study projects and on its expert medical team (radiologists, nuclear medicine physicians, gastroenterologists, cardiologists, neurologists, rheumatologists, dermatologists…).
cONTAcT: Lydia BEhLOUL [email protected]
International Offi cePhiladelphie (U.S.A)
1, Impasse Augustin Fresnel 44815 SAINT-HERBLAIN Tel: +33 (0)2 40 92 26 13 www.keosys.com
KEOSYS
SECTOR: • Diagnostic • R&D services/biotechnologies• Other: (developpement agency, association, institution, cluster)Medical Imaging Services for clinical TrialsTHERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
cONTAcT: Olivier hUMBEY [email protected]
24
Date of creation: 2009Number of employees: 5
Date of creation: 25/11/11
LEADS TO DEVELOPMENT (L2D) specializes in the early-stage development of therapeutic products. We offer consultancy, regulatory and operational management services to our clients in order to help them bridge the gap between therapeutic lead identifi cation and clinical development. Our clients benefi t from our development expertise without having to build additional internal headcount, whilst we ensure that their products are advanced rapidly and cost effectively to clinical proof of concept. We offer a personal service carefully tailored to our customers’ needs that maintains the transparency, fl exibility and availability associated with an internal team
LPS - BIOScIENcES is a European private company, providing services dealing with Endotoxins Technology.We provide services, products and partnerships to industrial companies and academics from human and animal health, cosmetic and food industry. Based on 40 years of know-how concerning LPS manipulation and structure to activity relationship, we enable our partners to use endotoxins for their therapeutic applications or to remove them from their production. We also run an innovative R&D project to create a new and powerful vaccine’s adjuvant
cONTAcT: J. [email protected]
cONTAcT: Frédéric cAROFFCEO [email protected]
leads to development166, boulevard du Montparnasse75014 PARIS www.leadstodevelopment.com
Génopôle4, Rue Pierre Fontaine 91058 EVRY Mob.: +33 (0)6 67 89 30 47 www.lpsbiosciences.com
SECTOR: R&D services/biotechnologies
SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologiesTHERAPEuTIC AREA: • Diseases of the blood, immune disorders • Infectious and parasistic diseases • Respiratory system
L2D SERvICES
LPS-BIOSCIENCES
25
Date of creation: 20/11/2008Number of employees: 6
METABOLYS has a drug discovery line in the diabetes fi eld. Six antidiabetic candidates are protected by 4 patents; one of them is being developed and will be out-licensed. METABOLYS has also a service activity consisting of predicting the safety and effi cacy of drug candidates using a metabolic fl ux analysis approach.
cONTAcT: Gabriel BAVEREL [email protected]
Laennec Faculty of Medicine7-11, rue G. Paradin 69008 LYON Mob.: +33 (0)6 84 85 57 75 www.metabolys.com
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Endocrine&metabolic diseases • Cancer, oncology
METABOLYS
Date of creation: 2002
MEDINcELL’s controlled-release delivery platform offers wide-ranging durations—from several days up to one year—for many small molecules and biologics, and requires no API modifi cation. Current commercial partnerships aim to address delivery hurdles across arthritis, oncology, contraception, diabetes, and our low-cost manufacturing enables partners to target fast-growing emerging markets.
cONTAcT: Sebastien [email protected]
International Offi ceMedinCell Corporation10451 Roselle St, Suite 200San Diego CA 92121
Parc Clément Ader1, avenue Charles Cros 34830 JACOU Tel: +33 (0)4 67 41 99 74 www.medincell.com
SECTOR: Therapeutics THERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
MEDINCELL
26
MYELOMAX is a french CRO specialized in preclinical evaluation services in the fi eld of multiple myeloma. Our mission is to assist our clients in the evaluation of drug effi cacy, mechanism of action, combination with approved drugs, identifi cation of biomarkers using our large and unique collection of Human Multiple Myeloma Cell Lines covering the molecular and functional diversity of Multiple Myeloma.
cONTAcT: [email protected]
IRS_UN 8, quai Moncousu 44007 NANTES Tel: +33 (0)2 28 08 00 40 www.myelomax.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cancer, oncology
MYELOMAX
Date of creation: 10/03/2009Number of employees: 30
METABRAIN is a diabetes research center (Paris area). Its 30 collaborators operate integrated and disease oriented medicinal chemistry, molecular, cellular and animal pharmacology, gather long term industrial experience in discovery and drug development. Since 2009, METABRAIN is conducting research partnerships with main French Biotechs and Pharmas. It develops drugs and nutraceuticals and associated biomarkers that address several interconnected chronic diseases such as diabetes, obesity, muscle dysfunction and memory troubles, for the elder population which requires alternatives to existing therapies.
cONTAcT: Valerie AUTIER [email protected]
4, avenue du pdt f. Mitterrand 91380 CHILLY MAZARIN Tel: +33 (0)1 69 19 41 50 www.metabrainresearch.com
SECTOR: • Therapeutics • Diagnostic • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Disease of nervous system• Endocrine&metabolic diseases
METABRAIN RESEARCH
27
OXELTIS
Date of creation: September 2010
OXELTIS is a medicinal chemistry service company delivering integrated solutions for managing and executing medicinal and fi ne organic chemistry projects in the fi eld of NCE discovery and optimization. OXELTIS is particularly active in the anti-infective and oncology fi elds. OXELTIS team expertise and background is related to medchem research for the past 10 years. Its expertise in organic chemistry is in heterocycles, macrocycles, sugars, nucleos(t)ides and phosphorus chemistry. OXELTIs is located in Montpellier-France and was founded in 2010 by former management and research team from Idenix Pharmaceuticals
cONTAcT: Jean-Marc ALLAIRE [email protected]
Cap Gamma1682, rue de la ValsièreC.S. 27384 34189 MONTPELLIER Cedex 4 Tel: +33 (0)4 99 23 50 36 www.oxeltis.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Infectious and parasistic diseases • Cancer, oncology
OTR3
Date of creation: July 2000Number of employees: 13
OTR3 is developing products in regenerative medicine from innovative proprietary molecules: the RGTA. RGTA are biodegradable polysaccharides engineered to restore the cellular microenvironment after lesion and favor tissue regeneration without external input of stem cells. Two products are on the market: CACIPLIQ20 and CACICOL20 to treat skin and corneal ulcers. Two developments are in clinical trials to treat mucositis and radiation dermatitis in cancer patients. Marketing authorization is expected within 1 year. OTR3 is looking for licensees and developments partners.
cONTAcT: Denis BARRITAULT [email protected]
4, rue Française 75001 PARIS Tel: +33 (0)1 83 62 78 83 www.otr3.com
SECTOR: Therapeutics THERAPEuTIC AREA: • Cancer,oncology • Skin&subcutaneous tissue
28
Date of creation: 1999Number of employees: 14 FTE
Date of creation: 1984
PELVIPhARM is a CRO delivering preclinical research services across a range of therapeutic areas including urology (BPH, OAB, NDO, SCI, SUI, IC…), sexual (ED, PE, FSD…) and cardiovascular medicine (Hypertension, Atherosclerosis, Metabolic Syndrome, Diabetes,Myocardial Infarction…). PELVIPhARM provides customized outsourcing services to clients according to their outsourcing needs, using both in vivo experimental models and in vitro animal and human tissue-based specifi c research services based on the most recent exploration methods.
PORSOLT is a long-established preclinical CRO with an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric & neurological diseases, acute & chronic pain, infl ammation, cardio vascular diseases, and metabolic disorders. PORSOLT also offers services for safety evaluation of drug candidates from screening to pre-Phase 1 regulatory studies (ICH S7), in full GLP compliance. PORSOLT’s safety program includes full assessment of arrhythmogenic risk and abuse/dependence liability.
cONTAcT: Delphine BEhR-ROUSSEL [email protected]
cONTAcT: Sébastien BREchE [email protected]
Orsay Parc86, rue de Paris 91400 ORSAY Tel: +33 (0)1 70 42 93 39 www.pelvipharm.com
Z.A. de Glatigné 53940 LE GENEST SAINT ISLE Tel: +33 (0)2 43 69 36 07 www.porsolt.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system• Disease of nervous system
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system• Disease of ear or eye
PELvIPHARM
PORSOLT
29
PRESTWIcK chEMIcAL is a drug discovery company that successfully identifi es hits for the project’s target and optimizes the hits into clinical candidates. With our premium partners, we have developed the capacity to integrate the whole drug research: Hit identifi cation using smart screening libraries and/or large scale pharmacophore based virtual screening, hit validation, hit to lead expansion, lead optimization and profi ling and have unprecedented success towards development.
POXEL is a biopharmaceutical company developing innovative fi rst-in-class drugs with a primary focus on Type 2 diabetes. The company develops novel treatments before partnering with pharmaceutical companies. POXEL operates independently as a lean organization with strong in-house drug development and business expertise. Its R&D pipeline consists in innovative programs with new mechanism of action, agents profi led for their activity on glucose metabolism and cardiovascular risk factors, all with an improved safety profi le compared to current available therapies.
cONTAcT: Paul BIKARD [email protected]
cONTAcT: Pascale MALGOUYRES [email protected]
220, boulevard Gonthier d’AndernachSTRASBOURG-ILLKIRCH Tel: +33 (0)3 69 20 16 00 www.prestwickchemical.com
200, avenue Jean Jaurès 69007 LYON Tel: +33 (0)4 37 37 20 10 www.poxel.com
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system • Disease of nervous system
SECTOR: • Therapeutics THERAPEuTIC AREA: • Endocrine&metabolic diseases
PRESTwICK CHEMICAL
POXEL
Date of creation: 1999
Date of creation: 2009Number of employees: 13
30
Date of creation: 2000
PX’ThERAPEUTIcS, located in Grenoble (France), provides services in the fi eld of recombinant protein development and GMP manufacturing. PX’ThERAPEUTIcS proposes custom programs targeting the development of monoclonal antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development up to clinical and small-scale commercial batch production, in bacteria, yeasts or mammalian cells. Our subsidiary Promise Advanced Proteomics provides products and services in the fi eld of quantitative proteomics.
cONTAcT: claire UNTEREINER [email protected]
Minatec BHT52A 7, parvis Louis Néel 38040 GRENOBLE Tel: +33 (0)4 38 02 36 50 www.px-therapeutics.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system • Diseases of the blood, immune disorders
PX’THERAPEuTICS
Date of creation: 2010
PUP PhARMA’s unique experimental services tailored to our customer’s specifi c perinatal and paediatric applications, allowed preclinical effi cacy and safety drug evaluation in the context of pathological/physiological conditions from prematurity to childhood. Our pharmacological services allow either complying with the mandatory Pediatric Investigation Plan or identifying new indications for yours products in the fi eld of Central Nervous System, Pulmonary or Infl ammatory Systems.
cONTAcT: David chAUVIER [email protected]
102, avenue Gaston Roussel 93230 Romainville Tel: +33 (0)9 81 30 80 12 www.puppharma.fr
PuP PHARMA
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Digestive system • Disease of nervous system • Injury, poisoning
31
Date of creation: 14/06/1999
SKULDTEch aims to discover and validate new genomic and pharmacogenomic biomarkers for diagnostics and therapeutic purposes. Its approach is based on “Digital Gene Expression” method, New Generation Sequencing (NGS) technologies associated with its proprietary bionformatics and biostatistics tools. This expertise enables the Company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new therapeutics especially in cancer, rare diseases and infectious diseases.
cONTAcT: Didier [email protected]
1682, rue de la Valsière C.S. 7739434184 MONTPELLIERTel: +33 (0)4 67 41 97 48www.skuldtech.com
SECTOR: • Diagnostic • R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Infectious and parasistic diseases • Cancer, oncology
SKuLDTECH
QUINTEN is a strategy and operations consulting fi rm specialized in leveraging biomedical data for pharmaceutical, biotechnology and cosmetics companies. QUINTEN’s knowhow complements traditional modeling and data-mining techniques, since it enables to identify, characterize and enhance the value of sub-groups corresponding to best and worst practice in terms of patients’ response or resistance to a treatment, and occurrence of undesirable side-effects.
cONTAcT: Alexandre TEMPLIER [email protected]
11, rue Galvani 75017 PARIS Tel: +33(0)1 45 74 33 05 www.quinten.com
THERAPEuTIC AREA: • Cardiovascular • Digestive system• Diseases of the blood, immune disorders
QuINTEN
Date of creation: 4/11/2008Number of employees: 15
32
Date of creation: 1987
TEXcELL is a world-renowned company that provides Biosafety and immunology services in full compliance with GLP and GMP standards.Thanks to our in-depth experience of providing viral safety testing and virus validation studies, we have provided support to a large number products licensed by the FDA, the EMA and the MHW. TEXcELL is also your central lab for pre-clinical and clinical trials. We offer a dedicated technology platform in immunology. Based in France near Paris (Evry), TEXcELL has also a subsidiary in USA, with facilities in Middletown, MD., and soon in Frederick, specialized in no GMP Cell culture and GLP compliant viral clearance testing services.
cONTAcT: Bernard PLIchON [email protected]
Bât. Genavenir 5 1, rue Pierre Fontaine 91058 EVRY Cedex Tel: +33 (0)1 60 91 33 10 www.texcell.com
SECTOR: R&D services/biotechnologies
TEXCELL
Date of creation: 2000Number of employees: 14
SYNcROSOME is focused on In Vivo Effi cacy Studies dedicated to Discovery and Preclinical stage with more than 25 Animal Models, to provide you the right data to make the right decision. We offer our services and our expertise in the development of drugs in: GASTROENTEROLOGY, cENTRAL NERVOUS SYSTEM, cARDIOVAScULAR, RESPIRATORY, INFLAMMATION. We perform also Pharmacokinetics studies (multi-species). Concerning PK studies, we pay a special attention to CNS-PK to evaluate the in vivo BBB passage of your compounds.
cONTAcT: Arnaud PEYRONNIER [email protected]
Case Postale 908Luminy biotech entreprises163, avenue de Luminy 13288 MARSEILLE Tel: +33 (0)4 95 05 31 80 www.syncrosome.com
SECTOR: R&D services/biotechnologies THERAPEuTIC AREA: • Cardiovascular • Digestive system• Disease of nervous system
SYNCROSOME
33
Date of creation: août 2012Number of employees: 6
VFP ThERAPIES is a young French company who has devised an innovative therapeutic approach aimed at treating brain diseases such as Alzheimer’s Disease by means of highly selective bioprecursor drugs. Such prodrugs do not deploy activity before they crossed the blood-brain-barrier, and hence do not induce signifi cant side effects. Besides, one so can target receptor sites in the brain in a more selective way. The required amount of active principle as well as its toxicity can thereby be decreased. The core business of VFP ThERAPIES is the development of proprietary drugs at the same time as joined development work on behalf of pharmaceutical and biotechnology companies.
cONTAcT: Francis MARSAIS President and CEO [email protected]
15, rue François Couperin76000 ROUEN Mob.: +33 (0)6 80 32 57 64 www.vfp-therapies.com
SECTOR: • Therapeutics • R&D services/biotechnologies THERAPEuTIC AREA: • Disease of nervous system • Mmental & behavioural disorders • Cancer, oncology
vfP THERAPIES
Date of creation: 2000
TROPhOS is a late stage pharmaceutical company whose strategy is to create and realise value from its proprietary, innovative, cholesterol-oximes compound family of mitochondrial pore modulators by taking at least one program to clinical validation for orphan/niche indications in neurology and acute cardiology before an exit for investors. The Company has its lead product, olesoxime (TRO19622), in phase 2/3 development and TRO40303 in phase 2 development with funding secured up to the next step of value creation.
cONTAcT: Julien [email protected]
Parc scientifi que de LuminyCase 93113288 MARSEILLETel: +33 (0)4 91 82 82 82www.trophos.com
SECTOR: Therapeutics THERAPEuTIC AREA: • Cardiovascular • Disease of nervous system
TROPHOS
VFP TherapiesDrugs : Highway to the Brain
C : 100 - m : 47 - j : 0 -n : 40
c : 100 -m : 10 -j : 0 -n : 10
TypographieCentury regular
WEBSITEwww.ubifrance.com
hEAD OFFIcE IN PARIS
77, boulevard Saint-Jacques 75014 PARIS - fRANCETel: +33 (0)1 40 73 33 88fax: +33 (0)1 40 73 30 39
Jennifer [email protected]
cONTAcT IN AUSTRIA uBIfRANCE viennaReisnerstrasse 50/10 1030 vIENNE - AuTRICHETel: +43 (0)1 712 63 57 64
Mascha [email protected]
BIO EUROPE 2O13 CONVENTION The French participation is organized by UBIFRANcE
